within Pharmacolibrary.Drugs.D_Dermatologicals.D11A_OtherDermatologicalPreparations.D11AH10_Lebrikizumab;
model Lebrikizumab 
   extends Pharmacolibrary.Drugs.ATC.D.D11AH10;

  annotation(Documentation(
    info ="<html><body><p>Lebrikizumab is a humanized monoclonal antibody that targets interleukin-13 (IL-13), a cytokine involved in the pathogenesis of atopic dermatitis and other inflammatory conditions. It is used primarily in the treatment of moderate-to-severe atopic dermatitis and is in clinical use and ongoing trials for this purpose. It is approved for use in several regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult subjects and patients with moderate-to-severe atopic dermatitis, based on population PK modeling.</p><h4>References</h4><ol><li><p>Datta-Mannan, A, et al., &amp; Lio, PA (2025). Evaluation of Pharmacokinetics of Lebrikizumab in Healthy Individuals After Subcutaneous Administration Using a Prefilled Syringe or Autoinjector in a Phase 1 Randomized Study. <i>Clinical therapeutics</i> 47(1) 55–61. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2024.10.016&quot;>10.1016/j.clinthera.2024.10.016</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39638723/&quot;>https://pubmed.ncbi.nlm.nih.gov/39638723</a></p></li><li><p>Noonan, M, et al., &amp; Matthews, JG (2013). Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. <i>The Journal of allergy and clinical immunology</i> 132(3) 567–574.e12. DOI:<a href=&quot;https://doi.org/10.1016/j.jaci.2013.03.051&quot;>10.1016/j.jaci.2013.03.051</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23726041/&quot;>https://pubmed.ncbi.nlm.nih.gov/23726041</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Lebrikizumab;
